Single nucleotide polymorphisms and cancer susceptibility.
Deng N, Zhou H, Fan H, Yuan Y. · 2017
Read Single nucleotide polymorphisms and cancer susceptibility. by Deng N, Zhou H, Fan H, Yuan Y. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5746410.txt.
Introduction
Deng and co-authors review how single letter DNA changes, called SNPs, affect cancer risk. Many cancer linked genes carry such changes. They sit in promoters, exons, introns, and the untranslated ends of genes. Each site changes gene activity in its own way.
Promoter changes alter factor binding and gene switching. Exon changes can quiet a gene, while intron changes reshape splicing. Changes in the tail ends affect translation and small RNA binding. Marks laid on DNA add a further layer of effects. The authors weigh the use of SNPs as signs for diagnosis and care.
Catalog record
| CREATOR | Deng N, Zhou H, Fan H, Yuan Y. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Single nucleotide polymorphisms and cancer susceptibility By Na Deng, Heng Zhou, Hua Fan, Yuan Yuan Published in: Oncotarget DOI: 10.18632/oncotarget.22372 ABSTRACT Abstract A large number of genes associated with various cancer types contain single nucleotide polymorphisms (SNPs). SNPs are located in gene promoters, exons, introns as well as 5'- and 3'- untranslated regions (UTRs) and affect gene expression by different mechanisms. These mechanisms depend on the role of the genetic elements in which the individual SNPs are located. Moreover, alterations in epigenetic regulation due to gene polymorphisms add to the complexity underlying cancer susceptibility related to SNPs. In this systematic review, we discuss the various genetic and epigenetic mechanisms involved in determining cancer susceptibility related to various SNPs located in different genetic elements. We also discuss the diagnostic potential of these SNPs and the focus for future studies. Keywords: single nucleotide polymorphism, genetic, epigenetic, susceptibility, cancer INTRODUCTION Single nucleotide polymorphisms (SNPs) are one of the most common types of genetic variations in the human genome. SNPs in genes that regulate DNA mismatch repair, cell cycle regulation, metabolism and immunity are associated with genetic susceptibility to cancer [1–12]. Understanding the mechanisms underlying the effects of SNPs that result in cancer susceptibility is critical to understanding the molecular pathogenesis of various cancers. From a clinical perspective, SNPs are potential diagnostic and therapeutic biomarkers in many cancer types. SNPs are located in different regions of genes such as promoters, exons, introns as well as 5′- and 3′ UTRs. Therefore, alterations in gene expression and their effect on cancer susceptibility vary depending on the location of the SNPs. The promoter region SNPs affect gene expression by altering promoter activity, transcription-factor binding, DNA methylation and histone modifications [13–20]. The exonal SNPs affect cancer susceptibility by suppressing gene transcription and translation [21–23]. SNPs in intron regions generate splice variants of transcripts and promote or disrupt binding and function of long non-coding RNAs (lncRNAs) [24–26]. SNPs in the 5′-UTR affect translation, whereas SNPs in the 3′-UTR affect microRNA (miRNA) binding [9, 27–29]. SNPs in regions that are located far from the actual genes reduce or enhance gene transcription through long-range cis effects [30]. In this systematic review, we discuss the genetic and epigenetic mechanisms that underlie the SNP-related cancer susceptibility and the potential utility of SNPs as cancer biomarkers. PROMOTER REGION SNPS AND CANCER SUSCEPTIBILITY The promoter region regulates the initiation and rate of gene transcription through cis-acting elements and trans-acting factors. Promoter-related polymorphisms affect transcription factor binding that alter promoter activity, gene transcription, mRNA stability and translation. Subsequently, these effects alter protein levels that potentially determine the individual's susceptibility to diseases including cancer. Moreover, polymorphisms in the promoter regions also affect cancer susceptibility by altering epigenetic mechanisms such as DNA methylation and histone modifications (Figure 1). [Figure: Schematic representation of mechanisms associated with promoter SNPs and cancer susceptibilitySNPs in transcription factor binding sites affect transcription factor binding to the gene promoter. SNPs in the TATA box affect promoter activity with A to C substitutions decreasing the number of the TATA boxes. SNPs in the CpG islands decrease methylation, affecting adjacent non-polymorphic CpG and transcription factor binding. The red triangle represents SNP; red arrows show substitutions of SNPs; red hollow circle represents unmethylated loci; red solid circle represents methylated loci.] Promoter region SNPs affect promoter activity Effect of promoter region SNPs on TATA box function Polymorphisms in the TATA box inhibit promoter activity and decrease genetic transcription because it is part of the core promoter. For example, a point mutation (A > C) at position -27 in the putative TATA box of the EDH17B2 gene decreases promoter activity [31]. Effect of promoter region SNPs on transcription factor binding The promoter region contains numerous binding sites for transcription factors that regulate gene transcription. Polymorphisms in the promoter region decrease the transcription of target genes by inhibiting the binding of the transcription factors to the promoter. The rs16260 (-160C > A) and rs5030625 (-347G-> GA) in the CDH1 promoter reduce transcriptional activity to different degrees [32, 33]. The rs16260(-160C > A) SNP decreases gene transcription by inhibiting transcription factor binding at the CDH1 promoter and promotes tumorigenesis, including prostate,breast, colon and pancreatic cancers, etc [32]. The CDH1 rs5030625 (-347G->GA) decreases CDH1 expression by 10-times (P < 0.001) via inhibiting transcription factor binding and correlates with increased familial gastric cancer susceptibility [33]. Conversely, APE1 rs1760944(-656T > G) is associated with increased transcription factor binding and higher cervical cancer risk [34]. Promoter region SNPs modulate binding between transcription factor and promoter based on the number of binding sites for transcription factors such as SP1, c-Myb, E2F1, Ets, and GATA-1. For example, the rs2596538 in the MICA promoter region increases the risk of hepatitis C virus-associated liver cancer (OR = 1.34) with the transcription factors binding to the G allele and not the A allele [35]. The rs689466 (-1195G > A) SNP in the promoter region of the COX-2 gene generates a new c-Myb binding site, thereby enhancing COX-2 expression and increasing the risk of oesophageal cancer by 1.72-fold (95% CI, 1.35–2.20) [36]. A T→G substitution rs2279744 in the promoter region of MDM2 increases transcriptional activity by enhancing the binding between the promoter and MDM2 transcripts; MDM2 overexpression mediated by cyclin D1 promotes tumorigenesis [37]. The rs1799750 -1607 1G→2G polymorphism in the MMP-1 promoter generates a Ets binding site that increases MMP-1 expression [38]. The C→T transitions at -1306 and -735 in the MMP-2 promoter eliminate a Sp1-binding site (CCACC box), thereby decreasing MMP-2 transcription and increasing the risk of esophageal squamous cell carcinoma (OR = 6.53; 95% CI = 2.78–15.33) [39]. The rs8179090 (-418G > C) in the TIMP-2 promoter eliminates the Sp1-binding site and decreases TIMP-2 expression [40]. SNPs in cis-acting elements such as GATA-1 transcription factor binding sites enhance the promoter activity of the survivin gene in breast cancer patients. For example, The G→A transitions at -235 SNP in the promoter of survivin gene generates a second GATA-1 binding site in its promoter region, thereby increasing survivin expression in breast cancer tissues [41]. Promoter region SNPs impact epigenetic mechanisms Effect of promoter region SNPs on DNA methylation DNA methylation occurs primarily in the CpG islands of the promoter region. Therefore, SNPs in the promoter region can alter DNA methylation status and profoundly impact gene expression. The SNPs associated with DNA methylation of CpG loci are referred to as methylation SNPs [15, 42–44]. SNPs in genes rich in G and C bases are frequently mutated in many human diseases. SNPs in the promoter region alter the number of CpG dinucleotides in a CpG island, leading to changes in methylation, histone acetylation, chromatin modification, and gene silencing [45]. Promoter region SNPs alter the number of methylation loci, thus changing gene expression and increasing the risk of cancer Some promoter region SNPs alter methylation in an allele-specific manner. Genome wide association studies (GWAS) showed that 38 SNPs in 12 CpG loci correlated with changes in methylation and expression of 10 genes (IRF6, TSPYL5, CRIM1, CHL1, DDT, PIGC, TMOD1, ZNF266, BDKRB2, GSTT1) [46]. Zhang et al. reported that the CHEK2 rs2236141 (-48 G > A) variant was associated with lower lung cancer risk (adjusted OR = 0.73) because it eliminated a methylation locus,